{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:34:24Z","timestamp":1793208864427,"version":"4.5.0"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100002283","name":"Alzheimer\u2019s Research UK","doi-asserted-by":"publisher","award":["CRTF2023B\u2010003"],"award-info":[{"award-number":["CRTF2023B\u2010003"]}],"id":[{"id":"10.13039\/501100002283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The recent publication of extension data from post\u2010regulatory trials of amyloid\u2010lowering antibody therapies, such as donanemab and lecanemab, requires clinicians to critically appraise trial designs and analyses in order to evaluate claims made by authors and sponsors of disease modification. This Perspective outlines the challenges with assessing claims of disease course modification, provides a framework for their evaluation, reviews the different trial designs and analytical approaches used to test or support them, and proposes a practical appraisal checklist for evaluating studies.<\/jats:p>","DOI":"10.1002\/alz.71643","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:04:27Z","timestamp":1782961467000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["What should convince a clinician of disease modification in Alzheimer's disease clinical trials?"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-4768","authenticated-orcid":false,"given":"Jemma","family":"Hazan","sequence":"first","affiliation":[{"name":"Division of Psychiatry University College London  London UK"},{"name":"North London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy Y.","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London  London UK"},{"name":"North London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London  London UK"},{"name":"North London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01569-z"},{"issue":"5","key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jama.2022.24490","article-title":"Lecanemab gains FDA approval for early Alzheimer disease","volume":"329","author":"Larkin HD","year":"2023","journal-title":"Jama"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02087-4"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.q2044"},{"key":"e_1_2_6_6_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Donanemab licensed for early stages of Alzheimer's disease in adult patients who have one or no copies of apolipoprotein E4 gene. Press release. October 23 2024. Accessed March 2 2026.https:\/\/www.gov.uk\/government\/news\/donanemab\u2010licensed\u2010for\u2010early\u2010stages\u2010of\u2010alzheimers\u2010disease\u2010in\u2010adult\u2010patients\u2010who\u2010have\u2010one\u2010or\u2010no\u2010copies\u2010of\u2010apolipoprotein\u2010e4\u2010gene"},{"key":"e_1_2_6_7_1","unstructured":"European Medicines Agency.Kisunla (donanemab). Published online October 2025. Accessed March 2 2026. efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.ema.europa.eu\/en\/documents\/overview\/kisunla\u2010epar\u2010medicine\u2010overview_en.pdf"},{"key":"e_1_2_6_8_1","unstructured":"European Medicines Agency.Leqembi (lecanemab) An overview of Leqembi and why it is authorised in the EU. Published online April 2025. Accessed March 2 2025. efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.ema.europa.eu\/en\/documents\/overview\/leqembi\u2010epar\u2010medicine\u2010overview_en.pdf"},{"issue":"2","key":"e_1_2_6_9_1","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings JL","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"2","key":"e_1_2_6_10_1","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer's disease","volume":"4","author":"Cummings J","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"e_1_2_6_11_1","unstructured":"European Medicines Agency.Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer's Disease. Committee for Medicinal Products for Human Use (CHMP);2018."},{"key":"e_1_2_6_12_1","unstructured":"U.S. Food and Drug Administration.Development & Approval Process | Drugs. August 8 2022.https:\/\/www.fda.gov\/drugs\/development\u2010approval\u2010process\u2010drugs#:~:text=Developed%20and%20Approved.\u2010 FDA%20Approval:%20What%20it%20means result%20of%20chance%20or%20bias"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2006.07.001"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0606-3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100446"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0815"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-179901"},{"key":"e_1_2_6_19_1","unstructured":"FDA.Early Alzheimer's Disease: Developing Drugs for Treatment. Center for Biologics Evaluation and Research Center for Drug Evaluation and Research;2024."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70291-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00391-w"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/1980-5764-dn-2025-e001"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70073-4"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00258-6"},{"key":"e_1_2_6_25_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration.Early Alzheimer's Disease: Developing Drugs for Treatment Guidance for Industry.2018."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0598-1"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119632"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1203730"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199601031-00009"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2018.1"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100480"},{"key":"e_1_2_6_33_1","unstructured":"Alzforum.TauRx Parses Subgroups to Make the Case for Methylene Blue Derivative Again. March 22 2024. Accessed May 15 2026.https:\/\/www.alzforum.org\/news\/conference\u2010coverage\/taurx\u2010parses\u2010subgroups\u2010make\u2010case\u2010methylene\u2010blue\u2010derivative\u2010again"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-023-00524-2"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2412-a"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-012-0047-7"},{"issue":"3","key":"e_1_2_6_37_1","first-page":"343","article-title":"Strategies for dealing with missing data in clinical trials: from design to analysis","volume":"86","author":"Dziura JD","year":"2013","journal-title":"Yale J Biol Med"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/biostatistics\/kxh001"},{"key":"e_1_2_6_39_1","first-page":"308","article-title":"Alzheimer's Disease Neuroimaging Initiative. The relative efficiency of time\u2010to\u2010progression and continuous measures of cognition in presymptomatic Alzheimer's disease","volume":"5","author":"Li D","year":"2019","journal-title":"Alzheimers Dement"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100511"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100587"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2026.100511"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71643","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:58:02Z","timestamp":1793206682000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/alz.71643"],"URL":"https:\/\/doi.org\/10.1002\/alz.71643","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71643"}}